Bristol-Myers Squibb Company (BMY)
Pre-market:
| Previous close | 42.27 |
| Open | 42.22 |
| Bid | 42.28 x 1100 |
| Ask | 42.75 x 2900 |
| Day's range | 41.91 - 42.99 |
| 52-week range | 41.91 - 66.46 |
| Volume | |
| Avg. volume | 15,552,998 |
| Market cap | 85.827B |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.10 |
| Earnings date | 26 July 2024 |
| Forward dividend & yield | 2.40 (5.67%) |
| Ex-dividend date | 04 Apr 2024 |
| 1y target est | 52.25 |
Business WireBristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
PRINCETON, N.J., May 23, 2024--Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
ZacksBristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).
ReutersBristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up from an earlier judgment of $834 million. The ruling from Judge James Ashford, of Hawaii's First Circuit Court, follows a non-jury trial held last fall. It was the second trial in the case, after the state's Supreme Court found that the judge in the first trial that resulted in the $834 million award had made a legal error.
